Tezepelumab treatment in severe asthma with recurrent chronic rhinosinusitis with nasal polyps: Case series
Background: Tezepelumab is a human IgG2 mAb that inhibits thymic stromal lymphopoietin (TSLP) and is approved for treatment of severe asthma. Bronchial asthma, usually a type 2 inflammatory disease, often co-occurs with chronic rhinosinusitis with nasal polyps (CRSwNP). However, tezepelumab has unkn...
Saved in:
| Main Author: | Yoshiro Kai, MD, PhD |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Journal of Allergy and Clinical Immunology: Global |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772829324001929 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tezepelumab achieves improvement of severe uncontrolled asthma and rhinosinusitis: Case series
by: Shigesato Inoue, MD, et al.
Published: (2025-05-01) -
Three-dimensional bronchial tree visualization in exercise-induced severe asthma following tezepelumab treatment
by: Yoshiro Kai, MD, PhD, et al.
Published: (2025-05-01) -
Tezepelumab for asthma with current or previous smoking habit: Case series
by: Yoshiro Kai, MD, PhD, et al.
Published: (2025-05-01) -
Impact of Comorbid Asthma on Life Quality of Patients with Chronic Rhinosinusitis and Nasal Polyps
by: Wu PW, et al.
Published: (2025-04-01) -
Lung function impairment and eosinophilia in patients with eosinophilic chronic rhinosinusitis
by: Yuki Sonoda, MD, et al.
Published: (2025-11-01)